ASTRAZENECA CANADA INC

With a strong focus on advancing science and innovative medicines, AstraZeneca Canada Inc. has invested nearly $5.5 million in a broad range of faculty, student, research and programmatic initiatives at the University of Toronto.

AstraZeneca Canada is one of the country’s leading contributors to the research and development of life-changing medicines.

The company has been a steadfast supporter of the University of Toronto for nearly four decades. Most recently, the company made a transformative investment to establish the Uro-Oncology Fellowship Fund at the Temerty Faculty of Medicine. This fund supports three fellows annually, providing them with hands-on clinical and research experience to foster the next generation of innovators and thought leaders in uro-oncology.

AstraZeneca Canada has also made significant contributions to endow key academic positions. The AstraZeneca Chair in Biotechnology at the University of Toronto Mississauga (UTM) is dedicated to improving health through education and research in drug discovery. The AstraZeneca Chair in Organic Synthesis, supports cutting-edge research into chemical compounds with potential pharmaceutical applications. Beyond these endowed chairs, AstraZeneca Canada’s gifts continue to support a variety of essential needs across learning, teaching and research at U of T.

Among its most major contributions is the establishment of the AstraZeneca Canada Centre for Information and Technology Literacy, located within the Hazel McCallion Academic Learning Centre at UTM. This advanced technology centre is open to all U of T students and offers access

to state-of-the-art workstations and specialized software to support their academic and research pursuits.

With its enduring partnership and shared vision with the University of Toronto, AstraZeneca Canada continues to advance excellence in education, helping to create a healthier future for communities across Canada and around the world.